James Mackin Sells 12,500 Shares of Artivion (NYSE:AORT) Stock

Key Points

• CEO James Mackin sold 12,500 shares of Artivion at an average price of $42.32, totaling approximately $529,000, reducing his ownership by 1.44%.
• Artivion's stock price decreased by 2.4% to $41.83, while the company reported a 15.3% increase in quarterly revenue year-over-year and earnings per share of $0.24.
• Analysts have varying ratings on Artivion, with target prices ranging from $33.00 to $42.00, reflecting a general optimism about the company's future performance.

Artivion, Inc. (NYSE:AORT - Get Free Report) CEO James Mackin sold 12,500 shares of the company's stock in a transaction on Friday, August 15th. The stock was sold at an average price of $42.32, for a total value of $529,000.00. Following the completion of the sale, the chief executive officer directly owned 852,783 shares in the company, valued at approximately $36,089,776.56. The trade was a 1.44% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Artivion Stock Down 2.4%

Shares of NYSE AORT traded down $1.0240 during trading on Tuesday, reaching $41.8260. The company had a trading volume of 268,651 shares, compared to its average volume of 443,577. Artivion, Inc. has a 12-month low of $21.97 and a 12-month high of $43.97. The stock has a market cap of $1.97 billion, a PE ratio of -99.49 and a beta of 1.64. The business's 50-day moving average is $32.50 and its 200 day moving average is $28.50. The company has a quick ratio of 3.48, a current ratio of 4.78 and a debt-to-equity ratio of 0.52.

Artivion (NYSE:AORT - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The company reported $0.24 EPS for the quarter, beating the consensus estimate of $0.11 by $0.13. The company had revenue of $112.97 million for the quarter, compared to analysts' expectations of $107.96 million. Artivion had a positive return on equity of 5.70% and a negative net margin of 4.43%.The firm's revenue for the quarter was up 15.3% compared to the same quarter last year. Artivion has set its FY 2025 guidance at EPS. As a group, equities analysts forecast that Artivion, Inc. will post 0.37 earnings per share for the current fiscal year.

Institutional Trading of Artivion

Hedge funds have recently modified their holdings of the stock. Legacy Advisors LLC purchased a new stake in shares of Artivion in the first quarter worth about $28,000. MCF Advisors LLC boosted its stake in shares of Artivion by 109.3% in the first quarter. MCF Advisors LLC now owns 1,176 shares of the company's stock worth $29,000 after buying an additional 614 shares during the last quarter. Smartleaf Asset Management LLC raised its holdings in Artivion by 47.7% in the 2nd quarter. Smartleaf Asset Management LLC now owns 1,667 shares of the company's stock worth $52,000 after purchasing an additional 538 shares during the period. Point72 Asia Singapore Pte. Ltd. acquired a new position in Artivion in the 4th quarter worth about $64,000. Finally, Tower Research Capital LLC TRC raised its holdings in Artivion by 447.6% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,410 shares of the company's stock worth $168,000 after purchasing an additional 4,422 shares during the period. Hedge funds and other institutional investors own 86.37% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the company. JMP Securities lifted their target price on Artivion from $33.00 to $42.00 and gave the company a "market outperform" rating in a research note on Friday, August 8th. Oppenheimer reiterated an "outperform" rating on shares of Artivion in a report on Friday, August 8th. Citizens Jmp upgraded Artivion to a "strong-buy" rating in a report on Tuesday, May 6th. Stifel Nicolaus boosted their price objective on Artivion from $36.00 to $40.00 and gave the company a "buy" rating in a report on Friday, August 8th. Finally, Wall Street Zen lowered Artivion from a "buy" rating to a "hold" rating in a research report on Sunday. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat, Artivion has an average rating of "Buy" and an average target price of $39.80.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.